← Back to dashboard
Stryker
Stryker's Mako franchise makes it one of the clearest scaled robotics names in orthopedics.
Metric timing
This page mixes live market data, trailing fundamentals, and latest reported statement data.
Live / market snapshot
Price, 1D change, market cap, and enterprise value are current market-based figures.
TTM / forward
Most valuation and margin cards are trailing twelve months, while forward P/E uses forward consensus.
Latest quarter / dividend cadence
Balance-sheet ratios use the latest reported quarter. Dividend cadence is inferred from recent payout history.
latest annual revenue
latest quarterly revenue
latest annual profit
latest quarterly profit
annualized per share
latest ex-dividend cash amount
Latest headlines
Recent company headlines. Each link opens the original article in a new tab.
The Robot Maker's Paradox
You can be forgiven for doing a double-take on Intuitive Surgical (ISRG) on Friday. The company posted second-quarter revenue of $2.89 billion, up 19% from a year ago and comfortably ahead of Wall Street estimates. Yet the stock ended the day down 14.1%, closing at a new 52-week low.
What's More Important For Intuitive Surgical: Today's Robots Or Tomorrow's Growth?The surgical robotics giant beat estimates, but a moderation in its core US market has investors questioning the whole story.
Stryker (SYK) Stock Looks Cheap On Cash Flow But Fair On EarningsStryker stock has given investors a 28.3% total return over the past five years, yet its current price around US$319.87 sits at a point where the Discounted Cash Flow (DCF) intrinsic value estimate suggests meaningful upside, while market based multiples look closer to fair. Over five years, Stryker has returned 28.3%, which points to steady but not dramatic long term gains for shareholders. New products such as the Mako RPS handheld robotic system can support expectations for future cash...
Mako Handheld Robotic Knee System Launch Might Change The Case For Investing In Stryker (SYK)On 16 July 2026, Stryker announced the U.S. commercial launch of Mako RPS, a handheld robotic system for total knee replacement that combines intraoperative planning with a robotically enabled saw and integrates with its Triathlon Total Knee System and Q Guidance platform. This move extends the Mako ecosystem beyond robotic-arm systems into handheld robotics, potentially broadening adoption by matching robotic precision with familiar surgical workflows. Next, we’ll explore how expanding the...
Stryker (SYK) Launches Mako RPS As Its Valuation Story Comes Into FocusStryker (SYK) has drawn fresh attention after announcing the U.S. commercial launch of Mako RPS, a handheld robotic system for total knee replacements that extends its established Mako orthopaedic robotics portfolio. See our latest analysis for Stryker. The U.S. launch of Mako RPS comes as Stryker’s share price sits at US$319.87 after a recent pullback, with a 30 day share price return of 6.22% but a 1 year total shareholder return that declined 17.02%. This suggests enthusiasm around its...
Stryker Launches Mako RPS to Expand Robotic Knee Surgery PortfolioSYK launches Mako RPS, expanding into handheld robotics for total knee replacement and broadening access to robotic-assisted orthopedic procedures.
Why it could benefit going forward
- Stryker's Mako franchise makes it one of the clearest scaled robotics names in orthopedics.
- Recent expansion into handheld robotics broadens the Mako platform and gives the sleeve another real medical-robotics leader.
- It adds exposure to hospital robotics without relying on the exact same thesis as Intuitive.
Moat / edge
- Established Mako installed base and surgeon workflow integration.
- Strong orthopedic distribution and clinical relationships.
- A robotics platform that can expand across procedures over time.
What to watch
- Mako placements and utilization.
- Adoption of new handheld robotics offerings.
- How much robotics continues to differentiate Stryker in orthopedics.
Key risks
- Hospital budgets and elective procedure trends can affect demand.
- The robotics narrative is important, but it still sits inside a broader medtech company.
Business snapshot
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.